Self‐Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments
Advanced Science · 2024-11 · 11 (41)
DOI: 10.1002/advs.202407043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.09.2024. Verfasst von Xuezhi Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China. Hauptthemen laut MEDLINE: Glaucoma, Reactive Oxygen Species, Prodrugs, Nanoparticles. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Glaucoma is an irreversible blinding eye disease characterized by retinal ganglion cell (RGC) death.Previous studies have demonstrated that protecting mitochondria and activating the CaMKII/CREB signaling pathway can effectively protect RGC and axon. However, currently treatments are often unsatisfactory, and the pathogenesis of glaucoma requires further elucidation. In this study, a ROS‐responsive dual drug conjugate (OLN monomer) is first designed that simultaneously bonds nicotinamide and oleic acid. The conjugate self‐assembled into nanoparticles (uhOLN‐NPs) through the aggregation of multiple micelles and possesses ROS scavenging capability. Then, a polymer with a hypoxic response function is designed, which encapsulates uhOLN‐NPs to form nanoparticles with hypoxic and ROS responses (HOLN‐NPs). Under hypoxia in RGCs, the azo bond of HOLN‐NPs breaks and releases uhOLN‐NPs. Meanwhile, under high ROS conditions, the thioketone bond broke, leading to the dissociation of nano‐prodrug. The released nicotinamide and oleic acid co‐scavenge ROS and activate the CaMKII/CREB pathway, protecting mitochondria in RGCs. HOLN‐NPs exhibit a significantly superior protective effect on R28 cells in glutamate models of glaucoma. The accumulation of HOLN‐NPs in retinal RGCs lead to significant inhibition of RGC apoptosis and axonal damage in vivo. Notably, HOLN‐NPs provide a new therapeutic approach for patients with neurodegenerative disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.
- Hunan Key Laboratory of Ophthalmology, Changsha, Hunan, 410008, P. R. China.
- National Clinical Research Center for Geriatric Diseases, Central South University, Changsha, Hunan, 410008, P. R. China.
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
- University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
- School of Dentistry, The University of Queensland, Brisbane, 4006, Australia.
ORCID-Profile: Dan Ji
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Zhou, X., Rong, R., Liang, G., Wu, Y., Xu, C., Xiao, H., Ji, D., & Xia, X. (2024). Self‐Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments. Advanced Science, 11(41). https://doi.org/10.1002/advs.202407043
Vancouver
Zhou X, Rong R, Liang G, Wu Y, Xu C, Xiao H, et al. Self‐Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments. Advanced Science. 2024;11(41). doi:10.1002/advs.202407043
BibTeX
@article{Zhou2024,
author = {Zhou, Xuezhi and Rong, Rong and Liang, Ganghao and Wu, Yukun and Xu, Chun and Xiao, Haihua and Ji, Dan and Xia, Xiaobo},
title = {Self‐Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {41},
doi = {10.1002/advs.202407043}
}
EUVIMED